Nilotinib in the Treatment of Systemic Sclerosis
NCT01166139
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Systemic Sclerosis
Interventions
DRUG:
Nilotinib (Tasigna)
Sponsor
Hospital for Special Surgery, New York
Collaborators
[object Object]
[object Object]